Potter Benjamin K, Rivera Julio A, Anderson Ashley B, Souza Jason M, Forsberg Jonathan A
Walter Reed National Military Medical Center, Uniformed Services University, Bethesda, MD, USA.
University of Pennsylvania Perelman School of Medicine, Department of Orthopaedic Surgery, Philadelphia, PA, USA.
Clin Orthop Relat Res. 2025 Mar 1;483(3):513-523. doi: 10.1097/CORR.0000000000003267. Epub 2025 Jan 31.
Individuals who have undergone transfemoral amputation often have difficulty donning and utilizing a conventional socket prosthesis. Osseointegrated prostheses may alleviate certain issues, potentially resulting in better outcomes, but few prospective studies have either evaluated these outcomes or quantified the purported benefits.
QUESTIONS/PURPOSES: (1) Did patient-reported outcome measures improve between baseline and 2-year follow-up among those who underwent osseointegration surgery after transfemoral amputation? (2) What was the frequency and severity of early complications related to the osseointegration procedures? (3) What was the minimum clinically important difference (MCID) in a global patient-reported outcome measure in this patient population?
Between October 2017 and October 2023, we recruited 41 participants to undergo transfemoral osseointegration surgery treated with the Osseointegrated Prostheses for the Rehabilitation of Amputees implant system for patients who had trouble utilizing traditional, socket-based prostheses. Of those, 5% (2 of 41) did not undergo surgery, 2% (1 of 41) were lost to follow-up, and 2% (1 of 41) died before the final 2-year follow-up, leaving 90% (37 of 41) for analysis in this prospective, observational trial. Participants were asked to complete the validated Questionnaire for Persons with a Transfemoral Amputation (Q-TFA) and the Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire before surgery as well as 3, 6, 12, and 24 months after the two-stage procedure. Thirty-seven participants (three women and 34 men; mean ± SD age 38 ± 10 years) reached the 24-month follow-up visit, and four patients were withdrawn. We tabulated the frequency and types of surgical complications that patients experienced and calculated the anchored-based MCID for the Q-TFA global score (0 to 100 maximum). The Q-TFA's global score is generated based on answers to three questions: "How would you summarize your level of function with your current prosthesis?", "How would you summarize the problems you experience with your current prosthesis?", and "How would you summarize your overall situation as an amputee?" Using the sum of the numerical scores for the three questions, we found the difference between the baseline and the final follow-up for the participants. Then, we took the first quartile of the difference to represent the median change in the lower 25% of the data and used this value as our MCID.
Scores in the study group improved in nearly all domains of the Q-TFA and PROMIS, including those related to prosthetic use, prosthetic mobility, and physical function (all p < 0.05). Patients developed superficial infections in 29% (15 of 51) of implanted limbs, all of which were treated successfully with antibiotics alone; 7 patients developed deep infections, only 1 of which involved the bone and implant. The anchor-based MCID in the Q-TFA global score was calculated as 17 of 100 for this study population.
Functional patient-reported outcomes improved in multiple domains among our patient cohort who underwent osseointegration surgery after transfemoral amputation, demonstrating the promise of this technology for patients with unsatisfactory function using conventional, socket-based prostheses. Infections and other complications were lower than in prior studies of osseointegration following limb loss. The novel MCID that we report can be used to determine whether patients have clinically important improvement in future osseointegration surgery studies comparing results between different implants, surgical techniques, and patient populations.
Level II, therapeutic study.
接受经股截肢的患者在穿戴和使用传统的接受腔假肢时常常遇到困难。骨整合假肢可能会缓解某些问题,有可能带来更好的效果,但很少有前瞻性研究评估这些效果或量化所谓的益处。
问题/目的:(1)在接受经股截肢后进行骨整合手术的患者中,患者报告的结局指标在基线和2年随访之间是否有所改善?(2)与骨整合手术相关的早期并发症的发生频率和严重程度如何?(3)该患者群体中,在一项整体的患者报告结局指标中,最小临床重要差异(MCID)是多少?
在2017年10月至2023年10月期间,我们招募了41名参与者,为那些在使用传统的基于接受腔的假肢时遇到困难的患者,采用截肢者康复用骨整合假肢植入系统进行经股骨整合手术。其中,5%(41名中的2名)未接受手术,2%(41名中的1名)失访,2%(41名中的1名)在最后的2年随访前死亡,在这项前瞻性观察性试验中,剩余90%(41名中的37名)用于分析。参与者被要求在手术前以及两阶段手术术后3、6、12和24个月完成经过验证的《经股截肢者问卷》(Q-TFA)和患者报告结局测量信息系统(PROMIS)问卷。37名参与者(3名女性和34名男性;平均±标准差年龄38±10岁)完成了24个月的随访,4名患者退出。我们将患者经历的手术并发症的频率和类型制成表格,并计算Q-TFA整体评分(满分0至100分)的基于锚定的MCID。Q-TFA的整体评分是根据对三个问题的回答得出的:“你如何总结你目前假肢的功能水平?”“你如何总结你在目前假肢上遇到的问题?”以及“你如何总结你作为一名截肢者的整体情况?”通过计算这三个问题的数字得分总和,我们得出了参与者在基线和最终随访之间的差异。然后,我们取差异的第一个四分位数来代表数据中较低25%的中位数变化,并将此值用作我们的MCID。
研究组在Q-TFA和PROMIS的几乎所有领域的得分都有所提高,包括与假肢使用、假肢移动性和身体功能相关的领域(所有p<0.05)。29%(51条植入肢体中的15条)的植入肢体发生了浅表感染,所有这些感染仅用抗生素就成功治愈;7名患者发生了深部感染,其中只有1例涉及骨骼和植入物。该研究人群中Q-TFA整体评分的基于锚定的MCID计算为100分中的17分。
在我们经股截肢后接受骨整合手术的患者队列中,患者报告的功能结局在多个领域得到改善,这表明该技术对于使用传统的基于接受腔的假肢功能不满意的患者具有前景。感染和其他并发症低于先前关于肢体缺失后骨整合的研究。我们报告的新的MCID可用于确定在未来比较不同植入物、手术技术和患者群体结果的骨整合手术研究中,患者是否有临床重要的改善。
II级,治疗性研究。